INTRODUCTION
============

Capsule endoscopy (CE) was introduced in 2001 for small bowel evaluation. Capsules designed for the esophagus and colon have shown promising results and are used in clinical practice \[[@b1-ce-2018-092]\]. However, the stomach has a large surface area and volume, and the gastric mucosa is difficult to observe entirely by CE. In clinical practice, it is relatively easy to identify and manage gastric lesions with flexible endoscopy, suggesting the limited role of CE for gastric lesions. This review focuses on the advantages and future direction of gastric CE while addressing current limitations.

CURRENT STATUS AND ADVANTAGES OF GASTRIC CE
===========================================

The swallowed capsule rapidly passes the proximal part of the stomach and usually remains in the antrum before entering the duodenum. Generally, the distal part of the stomach is easily observed with CE.

Vascular lesions such as gastric antral vascular ectasia are more easily detected with capsules than with conventional upper endoscopy \[[@b2-ce-2018-092],[@b3-ce-2018-092]\]. One possible reason is related to air insufflation. During esophagogastroduodenoscopy (EGD), air is insufflated to distend the stomach. In contrast, CE is performed under more physiological conditions. Increased intragastric pressure and flattened rugal folds diminish the blood flow to ectatic vessels. In addition, the close and magnified view of gastric mucosa provided by CE may allow better definition of subtle vascular changes \[[@b2-ce-2018-092],[@b4-ce-2018-092]\].

Interestingly, CE has been used to detect a lesion in the dark side of the pylorus, which is difficult to evaluate with conventional gastroscopy \[[@b5-ce-2018-092]\].

CURRENT LIMITATIONS OF CE FOR GASTRIC EVALUATION
================================================

Despite several advantages, CE has limited clinical use in the stomach mainly due to passive movement. In a study, the capsule was moved to each part of the stomach under gravity while changing the examinee's body position to detect intragastric lesions and normal gastric anatomy \[[@b6-ce-2018-092]\]. However, the result was not satisfactory and had limited value in the evaluation of gastric lesions.

In addition to restricted movement, CE has other limitations. CE cannot remove bubbles, exudate, and liquid material to obtain better images, cannot perform air insufflation to expand the stomach, and cannot perform diagnostic biopsy or therapeutic interventions \[[@b7-ce-2018-092]\]. The costs are still high compared to conventional endoscopy. Due to these limitations, CE is not performed for gastric evaluation in clinical practice. However, in 10%--20% of occult gastrointestinal bleeding, CE aided the detection of gastric or colonic lesions missed by EGD or colonoscopy \[[@b8-ce-2018-092],[@b9-ce-2018-092]\]. Therefore, when reviewing CE images, attention should be given to any gastric lesions that may have been missed with EGD.

CAPSULE WITH ACTIVE LOCOMOTION SYSTEM
=====================================

Several studies have attempted to overcome the limitations of CE in gastric evaluation. Because gastric evaluation using spontaneous bowel motion or altered body position has very limited use, many studies have been performed to develop capsules with active locomotion systems \[[@b10-ce-2018-092]\]. Active locomotion systems mainly use two methods: in one, an internal locomotion system uses an embedded on-board miniaturized actuator (e.g., embedded motorized propeller for locomotion in a liquid environment); the other uses an external locomotion system that relies on magnetic force to control capsule movement \[[@b11-ce-2018-092]-[@b13-ce-2018-092]\].

In the study of active capsule locomotion systems, magnetic-controlled CE has been used most extensively and has provided some clinical data ([Table 1](#t1-ce-2018-092){ref-type="table"}) \[[@b11-ce-2018-092]\]. In the magnetic-controlled system, capsule movement occurs either with a handheld external magnet \[[@b14-ce-2018-092]-[@b17-ce-2018-092]\] or with a robot-guided magnet through a computer workstation ([Figs. 1](#f1-ce-2018-092){ref-type="fig"}-[](#f2-ce-2018-092){ref-type="fig"}[3](#f3-ce-2018-092){ref-type="fig"}) \[[@b18-ce-2018-092]-[@b27-ce-2018-092]\]. Robotic control is more precise and reliable than manual control \[[@b21-ce-2018-092],[@b25-ce-2018-092]\]; however, both methods have yet to achieve performance in detailed gastric evaluation comparable to that of EGD. In recent studies, robot-guided magnetic-controlled CE showed promising results in detecting gastric lesions with accuracy comparable to that of conventional gastroscopy \[[@b26-ce-2018-092],[@b27-ce-2018-092]\]. In most clinical trials for gastric evaluation, CE showed accuracy comparable to that of conventional gastroscopy, but some lesions were detected more sensitively with CE. These were small hyperplastic polyps and angiomas \[[@b4-ce-2018-092]\]. This might be due to the longer examination time or magnified view of CE. However, these finding did not influence the main diagnostic outcomes of conventional endoscopy. The rate of adverse events during magnetic-assisted CE for gastric evaluation was 1%--4% ([Table 1](#t1-ce-2018-092){ref-type="table"}). All reported events were without significant sequelae and resolved completely a few hours or days later (e.g., abdominal distension, nausea, vomiting, foreign body sensation, and inability to swallow the capsule) \[[@b4-ce-2018-092],[@b26-ce-2018-092],[@b27-ce-2018-092]\]. Most events seemed to be related to gastric preparation to distend the stomach, which varies slightly among studies but usually involves drinking 400--1,000 mL of water. It is expected that technical advances may facilitate a significant role for magnetic-controlled CE in gastric disease management in the near future.

For internal locomotion, several types of platforms have been developed, including leg-based capsules \[[@b28-ce-2018-092]-[@b31-ce-2018-092]\], paddling-based technique \[[@b32-ce-2018-092],[@b33-ce-2018-092]\], and an earthworm-like mechanism \[[@b34-ce-2018-092],[@b35-ce-2018-092]\], but only a propeller-based locomotion system has undergone continuous study, with several published reports of basic mechanical and in vivo animal studies. However, this system is still in the experimental stage, with clinical trials yet to be performed \[[@b12-ce-2018-092],[@b36-ce-2018-092]-[@b38-ce-2018-092]\]. The most significant drawback of an internal locomotion system is mechanical complexity requiring large on-board volume and a large power supply. Because of these limitations, magnetic-controlled external locomotion systems have drawn more interest \[[@b11-ce-2018-092]\].

TRIALS TO OVERCOME LIMITATIONS OTHER THAN LOCOMOTION
====================================================

During CE, the stomach is in a collapsed state and CE cannot expose the entire gastric mucosa. Air insufflation devices have been developed and ex vivo and in vivo animal studies have been conducted. However, no clinical trial has been performed for gastric evaluation \[[@b39-ce-2018-092],[@b40-ce-2018-092]\]. In several clinical trials of magnetic-controlled CE for gastric evaluation, orally instilled air-generating powder has been used to achieve adequate gastric distension, especially for the proximal stomach, but resulted in suboptimal visualization \[[@b16-ce-2018-092],[@b21-ce-2018-092],[@b27-ce-2018-092],[@b41-ce-2018-092]\].

For optical enhancement and more accurate diagnosis, flexible spectral imaging color enhancement has been implemented using the CE workstation with improved detection of small bowel lesions \[[@b42-ce-2018-092],[@b43-ce-2018-092]\].

Several attempts have been made to implement active diagnostic and therapeutic modalities in CE, such as biopsy \[[@b44-ce-2018-092],[@b45-ce-2018-092]\], clipping \[[@b46-ce-2018-092]\], and thermal coagulation \[[@b47-ce-2018-092]\]. These methods have not yet undergone clinical trials.

FUTURE PERSPECTIVES OF CE FOR GASTRIC EVALUATION
================================================

CE for gastric evaluation has limitations similar to that of CE for other gastrointestinal regions, but also has specific considerations associated with gastric anatomy. The stomach is a spacious organ with an irregular shape requiring a sophisticated active locomotion platform, compared to that for other parts of the gastrointestinal tract, explaining why most research on gastric evaluation using CE has focused on active locomotion systems. Magnetic-assisted CE has been studied most extensively. However, the distance between the ventral skin surface and gastric fundus is longer than the distance between ventral skin and antrum, making evaluation of the fundic area difficult \[[@b48-ce-2018-092]\]. In addition, the collapsed state of the fundus during CE makes evaluation more difficult. Thus, further studies are required to identify the most effective and safe magnet strength needed to manipulate CE in the proximal gastric area as well as to identify a satisfactory method of gastric distension \[[@b41-ce-2018-092]\].

With rapid technological advances, current limitations will be overcome and costs will decrease. Because of the innate advantages of CE, which is non-invasive, safe, and patient-friendly, current limitations will be overcome to make CE a screening tool superior to that of conventional gastroscopy. These advantages have especially significant clinical implications in countries with national gastric cancer screening programs, as in Korea. If artificial intelligence (AI) is combined with capsule endoscopic image interpretation, automated gastric evaluation without involvement of medical professionals will be possible. Patients can easily perform gastric self-evaluation. Only those with suspected pathology on CE imaging with AI-assisted interpretation, using settings to detect lesions with high sensitivity, will be examined by a physician and undergo conventional gastric endoscopy. For this scenario to be realized, current obstacles that must be overcome are air insufflation, sophisticated active locomotion, correct localization of CE in the body, and sensitive AI-assisted interpretation of CE imaging.

CONCLUSIONS
===========

The clinical significance of CE in the evaluation of gastric pathology is very limited. However, due to patient-friendly, non-invasive, and safe features requiring no sedation, trials to develop more sophisticated CE control systems are continuing. In the near future, technical improvements including integration with AI may facilitate the application of CE as an important medical device not only in the small bowel but also for gastric lesion evaluation and management. We dare to predict that the entire gastrointestinal tract can be evaluated with CE (pan-endoscopy) in the future.
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![System jointly developed by Olympus and Siemens (robot-assisted manipulation). (A) Capsule endoscope. (B) Guidance magnet. (C) User interface. Adapted from Keller et al. \[[@b22-ce-2018-092]\] with permission from IEEE.](ce-2018-092f1){#f1-ce-2018-092}

![NaviCam capsule endoscope and magnetic control system (robot-assisted manipulation). (A) NaviCam capsule endoscope. (B) NaviCam magnetic control system. Adapted from Liao et al. \[[@b26-ce-2018-092]\] with permission from Elsevier.](ce-2018-092f2){#f2-ce-2018-092}

![MiroCam-Navi system (hand-held manipulation). (A) Real-time viewer. (B) Receiver and sensor. (C) Hand-held magnet. (D) MiroCam-Navi capsule. Adapted from Rahman et al. \[[@b14-ce-2018-092]\] with permission from Elsevier.](ce-2018-092f3){#f3-ce-2018-092}

###### 

Clinical Trials of Capsule Endoscopy in Gastric Evaluation

  Author                                                                                     Year   Actuation mode           Manipulation             *n*   Study design                                                               Accuracy for gastric lesions                        Safety (adverse events)   Note
  ------------------------------------------------------------------------------------------ ------ ------------------------ ------------------------ ----- -------------------------------------------------------------------------- --------------------------------------------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  Swain et al. \[[@b17-ce-2018-092]\]                                                        2010   External magnetic        Hand-held magnet         1     Pilot study (case report)                                                  N/A                                                 none                      First human trial
  Modified colon capsule (Given Imaging Ltd., Yoqneam, Israel) with external magnet paddle                                                                                                                                                                                                                           
  Rey et al. \[[@b23-ce-2018-092]\]                                                          2010   External magnetic        Robotic control          53    Pilot study (case series)                                                  N/A                                                 0%                        Magnetic driving system jointly developed by Olympus Medical Systems Corporation (Tokyo, Japan) and Siemens Healthcare (Erlangen, Germany)
  Keller et al. \[[@b16-ce-2018-092]\]                                                       2011   External magnetic        Hand-held magnet         10    Pilot study (case series)                                                  N/A                                                 0%                        Modified colon capsule (Given Imaging Ltd.) with external magnet paddle
  Liao et al. \[[@b21-ce-2018-092]\]                                                         2012   External magnetic        Robotic control          34    Pilot study (case series)                                                  N/A                                                 0%                        NaviCam (Ankon Technologies Co. Ltd., Wuhan, China)
  Rey et al. \[[@b4-ce-2018-092]\]                                                           2012   External magnetic        Robotic control          61    Pilot study (single-center, prospective, self-controlled, blinded trial)   N/A                                                 3/61 (4.9%)               Magnetic driving system jointly developed by Olympus Medical Systems Corporation and Siemens Healthcare
  Jun et al. \[[@b6-ce-2018-092]\]                                                           2013   Passive (no actuation)   Passive (no actuation)   8     Pilot study (case series)                                                  50%^[a)](#tfn1-ce-2018-092){ref-type="table-fn"}^   0%                        PillCam ESO (Given Imaging Ltd.) with various position changes
  Denzer et al. \[[@b24-ce-2018-092]\]                                                       2015   External magnetic        Robotic control          189   Two-center, prospective, self-controlled, blinded trial                    88.1%--90.5%                                        0%                        PillCam ESO (Given Imaging Ltd.) with innominate magnetic guidance system
  Zou et al. \[[@b27-ce-2018-092]\]                                                          2015   External magnetic        Robotic control          68    Two-center, prospective, self-controlled, blinded trial                    91.2%                                               3/68 (4.4%)               NaviCam (Ankon Technologies Co. Ltd.)
  Qian et al. \[[@b18-ce-2018-092]\]                                                         2016   External magnetic        Robotic control          60    Case series                                                                N/A                                                 N/A                       NaviCam (Ankon Technologies Co. Ltd.)
  Liao et al. \[[@b26-ce-2018-092]\]                                                         2016   External magnetic        Robotic control          350   Multicenter, prospective, self-controlled, blinded trial                   93.4%                                               5/350 (1.4%)              NaviCam (Ankon Technologies Co. Ltd.)
  Rahman et al. \[[@b14-ce-2018-092]\]                                                       2016   External magnetic        Hand-held magnet         26    Pilot study (self-controlled comparative study)                            96%^[a)](#tfn1-ce-2018-092){ref-type="table-fn"}^   N/A                       MiroCam-Navi (Intromedic Ltd., Seoul, Korea)

N/A, not applicable.

Not presented, but calculated from the results of manuscript.
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